We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 17, 2019

Response-Adapted Treatment With Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed by Rituximab Maintenance in Patients With Relapsed or Refractory Follicular Lymphoma After First-Line Immunochemotherapy

Cancer Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

Cancer Medicine
Response-Adapted Treatment With Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed by Rituximab Maintenance in Patients With Relapsed or Refractory Follicular Lymphoma After First-Line Immunochemotherapy: Results of the RBMDGELTAMO08 Phase II Trial
Cancer Med 2019 Oct 01;[EPub Ahead of Print], FJ Peñalver, JA Márquez, S Durán, P Giraldo, A Martín, C Montalbán, JM Sancho, MJ Ramírez, MJ Terol, FJ Capote, A Gutiérrez, B Sánchez, A López, A Salar, G Rodríguez-Caravaca, M Canales, MD Caballero

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading